by defining robust cut-off values in a larger, well-defined (international) reference cohort. Such future studies may also allow determination of clinically relevant thresholds in heterogenous samples. Other advantages are the potential for automation and the relatively low costs. We conclude that this type of functional read-out for p53 could be a valuable contribution to diagnostic and therapeutic criteria, and should be further tested in the prospective clinical trials.
Immunoglobulin and T-cell receptor gene rearrangements as PCR-based targets are stable markers for monitoring minimal residual disease in acute lymphoblastic leukemia after stem cell transplantation Alterations of phenotypic or genotypic markers because of clonal development or selection between disease episodes interfere with the detection of minimal residual disease (MRD) in acute leukemia. This issue has been investigated extensively for relapses after induction and reinduction therapy in acute lymphoblastic leukemia (ALL), in which the usage of rearranged immunogenes is well established (Szczepanski et al. 1 and Guggemos et al., 2 and references therein). Currently, allogeneic hematopoietic stem cell transplantation (SCT) is the only curative treatment for many high-risk patients with ALL, but relapse is still the most frequent reason for treatment failure. MRD studies after SCT have shown significant associations between MRD positivity and relapse, [3] [4] [5] [6] and, therefore, these studies could form the basis for further interventional preemptive immunotherapy strategies to prevent relapse. With regard to marker stability, however, these studies either did not compare junctional region sequences or limited their investigations to particular gene loci.
Detailed sequencing analysis of immunoglobulin and T-cell receptor (Ig/TCR) rearrangements is the most reliable way to understand how rearrangements persist or evolve during the course of the disease. To assess the extent of marker changes after allogeneic SCT, we performed a retrospective analysis by characterizing currently used IgH, IgK-deletion (IgK-Kde), TCR-g, TCR-d and TCR-b gene rearrangements with BIOMED-1 and BIOMED-2 primers 7, 8 for target identification and subsequent sequence analyses according to the European Study group on MRD detection in ALL (ESG-MRD-ALL). 9 We compared leukemia blast samples from the initial or relapse diagnosis with samples from a subsequent relapse after allogeneic SCT. The cases included 40 pediatric and adolescent ALL patients who suffered a relapse after undergoing allogeneic SCT in the first (CR1, n ¼ 8) and either the second (CR2, n ¼ 25) or the third (CR3, n ¼ 7) complete remissions between 1997 and 2006. Of these patients, 38 were diagnosed for precursor B-ALL and 2 for T-ALL. All patients were pretreated according to the protocols ALL-BFM (n ¼ 7), ALL-REZ-BFM (n ¼ 32) of the Berlin-Frankfurt-Münster Group and CoALL (n ¼ 1) of the German Cooperative Study Group for Childhood ALL. The median age at transplantation was 10.2 years, ranging from 1.5 to 22.2 years. Relapse occurred between 54 and 1188 days (3.3 years) after transplantation (median: 0.61 years), without significant differences between patients transplanted in the CR1 (median 0.47 years), CR2 (median 0.93 years) and CR3 (median 0.49 years). The inclusion of the patients was based on the availability of paired samples at the time of the primary or relapse diagnosis as well as at relapse after allogeneic SCT. For all patients involved in this study, protocols were approved by the local ethical committees. Written informed consent was obtained from the patients or their guardians for sample collection following diagnosis according to the Declaration of Helsinki.
In total, we analyzed 133 Ig and TCR gene rearrangements in samples preceding transplantation and 140 after subsequent relapse (Table 1 and Supplementary Information). The observed marker frequency (Table 2) shows considerable convergence to the recently published study by Flohr et al., 10 which reports the most comprehensive data concerning the incidence of Ig/TCR rearrangements in childhood ALL. Although the patient cohort is not comparable to that of our study, this observation indicates that the detection of markers was not substantially affected by methodological peculiarities of the laboratory.
Of all patients, the median marker number of pre-and post-SCT was three rearrangements per individual; this value is obviously lower when compared to the studies that have used similar target detection approaches during CR1. 1, 11 We assume an association with the advanced disease duration of most patients. This assumption is supported by our observation that those patients transplanted during CR1 had a median marker number of five, whereas those with advanced disease that were transplanted during CR2 or CR3 showed a median marker number of three (Mann-Whitney test, P ¼ 0.04). The number of rearrangements is not associated with patient age or disease phenotype.
Most analyzed junctions are comprised of monoallelic rearrangements ( Table 2 ). The occurrence of biallelic and oligoallelic gene rearrangements is low in comparison to the most comprehensive study of MRD-PCR targets in relapse samples after induction therapy performed by Szczepanski et al. 1 Depending on the gene loci, these authors reported biallelic and oligoclonal configurations in up to 88 and 42% of rearranged gene loci, respectively. In contrast, we observed biallelic configurations in up to 38% and oligoclonality in up to 16% of the rearranged gene loci. As oligoclonality is the most powerful predictor of clonal evolution, 1 this observation confirms the comparatively high stability of markers after SCT. For instance, of the 133 initially diagnosed rearrangements, 116 (87%) were completely preserved; only 24 (17%) of the 140 markers analyzed at relapse were considered to be newly Letters to the Editor emerged. Of those, five cases showed sequence homology through shared germline elements between the sample preceding transplantation and the sample of relapse thereafter; this finding is suggestive of an ongoing recombination process (Table 3) . Even though the number of changes seemed to be slightly higher for TCRD, none of the investigated gene loci showed a significant predisposition toward marker alteration. If marker loss is used as a criterion, the estimated stability was highest for TCRB (100%); this gene rearrangement showed the lowest frequency. IgH, TCRG and IgK-Kde showed stabilities of 90%. The most frequent deviation was observed for TCRD, where 75% of all junctions were retained at relapse. New rearrangements occurred in TCRB with a frequency of 8%, IgH with a frequency of 14%, IgK-Kde with a frequency of 16%, TCRG with a frequency of 18% and TCRD with a frequency of 25%.
As alterations obviously involved a minority of markers, it is not surprising that all patients retained a minimum of one rearrangement. This proved in all cases the clonal relationship between blasts at both relapse and the initial or the relapse diagnosis before SCT. Moreover, a substantial number of patients were absolutely unaffected by marker changes. Clonal stability was observed for half of the patients, whereas we observed varying extents of deviation for the other 20 patients. In five patients, the loss of one initially analyzed rearrangement was observed along with a median marker number decrease from 3 to 2. In nine patients, one or two additional new sequences were detectable as the median marker number increased from three to four. In six patients, both absence of initially detected rearrangements and the appearance of new rearrangements were observed along with stable rearrangements in the relapse sample. The median marker number decreased slightly from 5 to 4.5 between these time points. Additionally, these six patients revealed several characteristics that differentiated them from the other groups. These characteristics may indicate the association of marker number, oligoclonality and clonal development. The average marker number per patient was significantly higher than the other patients (P ¼ 0.0035, unpaired t-test). Exactly 50% of these patients underwent their transplants in CR1, and all patients showed bi-, tri-or tetraallelic rearrangements. Furthermore, all rearrangements that indicated ongoing recombination at relapse, as signified by the presence of different junctional sequences in combination with shared germline elements, are found within this group (Tables 1  and 3) .
For the investigated patients, the loss and gain of markers more or less balanced one another. With regard to the generation of false-negative results, however, the loss of markers is of more importance than the gain of new ones; this is particularly true if markers are coincidentally conserved. As stated above, 11 patients showed marker loss, whereas the pattern of changes was restricted to the appearance of newly detectable sequences in nine patients. Hence, in 29 patients (73%), all initially diagnosed markers were preserved. We observed a considerably higher stability of MRD markers than reported by other studies concerning relapse after induction or reinduction therapy. Such studies have reported preservation of all MRD-PCR targets in 38% of patients at the first relapse 1 and 52% of patients at the second relapse. 2 The difference might be Table 2 The incidence of IgH, IgK-Kde, TCRG, TCRD and TCRB gene rearrangements and mono-, bi, and oligoallelic configurations before transplantation (A) and at subsequent relapse (B) Monoallelic rearrangements represent most potentially one clone. Biallelic rearrangements could reflect a recombination of both alleles, but the optional possible detection of two cell clones cannot be excluded. Accordingly, more than two rearrangements at one locus are indicative of oligoclonality, but they might also result from hyperdiploid aneuploidy. Table 3 Rearrangements Letters to the Editor explained by particular characteristics of the patients in this study. In marked contrast to those studies, our cohort consists exclusively of patients with the highest risk of relapse indicated for SCT according to the BFM criteria. For those patients, one postulated mechanism for clonal development (that is, the selection of resistant clones) might be of minor relevance due to the refractory property of the leukemia. Nevertheless, our results definitely underline the need for an approach considering more than one marker for monitoring MRD. We estimated the effort required not to miss a relapsing clone in the worst case scenario (that is, when all lost markers belonged to those selected for monitoring). Theoretically, all patients could reliably be monitored with the usage of four markers, 98% with three markers and 90% with two markers. With regard to reliability, these results suggest a three-marker approach. However, for the majority of patients, such an approach is scarcely feasible, because of the constrained marker repertoire, which was shown for the 25 patients (23 B-ALL and 2 T-ALL) who exhibited only three or fewer rearrangements. For these patients, target selection must be based predominantly on the availability of suitable junctional sequences. This might impede MRD detection, as not all gene loci or junctional sequences are equally eligible. For example, TCRG gene rearrangements are generally less sensitive markers in real-time quantitative PCR analyses, due to their limited combinatorial diversity and the abundance of polyclonal Vg-Jg joinings in normal T cells. 1 However, they have to be used frequently for MRD detection in advanced stage disease patients.
To increase the availability of suitable markers, we obviously must expand the number of screened gene loci. For instance, the TCRB rearrangements, which were not included in other studies, 1,2 provided informative and stable targets in 13% of B-lineage ALL patients. This finding shows one principal method to improve the reliability of MRD monitoring for this particular group of patients, which shows substantially higher stability of Ig/TCR rearrangements than reported in earlier studies concerning patients receiving predominantly polychemotherapy before the first 1 or second 2 relapse.
